Statins, Fibrates, or Niacin: A Lipid Therapy Guide for NP Board Exam Prep
Last updated: June 2026 — Reviewed by Shaira Cohen, MSN, APRN, FNP-C, CNE
Lipid management is a guaranteed topic on the nurse practitioner board exams, and one question style appears again and again: given a patient's lipid panel and risk profile, should you reach for statins, fibrates, or niacin? Each drug class lowers different lipids, has different outcome evidence, and occupies a different place in current guidelines.
This guide compares statins, fibrates, and niacin the way the AANP and ANCC test them — by mechanism, indication, and monitoring — so you can confidently match the right agent to the right patient. It closes with a statin intensity chart, a full comparison table, and board-style practice questions.
Why Lipid Therapy Is Risk-Based, Not Number-Based
Modern lipid management is built around atherosclerotic cardiovascular disease (ASCVD) risk reduction, not simply chasing an LDL number. The central question is: will lowering this patient's lipids reduce heart attacks and strokes?
That framing explains the entire hierarchy. Statins sit at the top because they have the strongest outcome evidence — decades of randomized trial data showing reduced mortality and cardiovascular events. Fibrates have a narrow but important niche. Niacin has largely fallen out of favor despite favorable effects on the lipid panel, because those effects did not translate into better outcomes.
Statins: The First-Line Choice
Statins (HMG-CoA reductase inhibitors) block cholesterol synthesis in the liver, which upregulates LDL receptors and clears LDL from the blood. They are first-line for LDL lowering and ASCVD risk reduction because they have by far the strongest mortality and event data.
Statin Intensity
Statins are dosed by intensity, defined by how much they lower LDL. The ACC/AHA classifies statins into three tiers:
- High-intensity — lowers LDL by ≥50%
- Moderate-intensity — lowers LDL by 30–49%
- Low-intensity — lowers LDL by <30% data-preserve-html-node="true"
The table below maps the most-tested agents to their intensity level. This is among the highest-yield tables in lipid pharmacology for the boards.
| Drug | Dose | Intensity | LDL Reduction |
|---|---|---|---|
| Atorvastatin | 40–80 mg | High | ≥50% |
| Rosuvastatin | 20–40 mg | High | ≥50% |
| Atorvastatin | 10–20 mg | Moderate | 30–49% |
| Rosuvastatin | 5–10 mg | Moderate | 30–49% |
| Simvastatin | 20–40 mg | Moderate | 30–49% |
| Pravastatin | 40–80 mg | Moderate | 30–49% |
| Simvastatin | 10 mg | Low | <30% |
| Pravastatin | 10–20 mg | Low | <30% |
| Lovastatin | 20 mg | Low | <30% |
Who Gets a Statin?
Current ACC/AHA guidance identifies four major statin benefit groups:
- Clinical ASCVD — known coronary disease, prior stroke/TIA, or peripheral arterial disease → high-intensity statin
- LDL ≥ 190 mg/dL — including familial hypercholesterolemia → high-intensity statin
- Diabetes, age 40–75 → at least a moderate-intensity statin
- Primary prevention, age 40–75 — statin decision guided by the 10-year ASCVD risk estimate, often refined with a coronary artery calcium score and risk-enhancing factors
Key point for boards: Match each benefit group to its intensity. Clinical ASCVD and LDL ≥ 190 both get high-intensity. Diabetes in the 40–75 window gets at least moderate. Primary prevention is a risk calculator decision — not automatic.
Statin Monitoring and Adverse Effects
Obtain a baseline lipid panel and recheck roughly 4–12 weeks after starting or adjusting therapy to assess adherence and response. The most common complaint is myalgia; true myopathy and rhabdomyolysis are rare. Check a creatine kinase (CK) level if a patient reports significant muscle symptoms. Statins can mildly raise transaminases and modestly increase the risk of new-onset diabetes — neither effect outweighs the cardiovascular benefit in patients who meet treatment criteria.
Drill cardiovascular and pharmacology questions in the NP Question Bank
Fibrates: For Severe Hypertriglyceridemia
Fibrates (gemfibrozil, fenofibrate) are PPAR-alpha agonists. Their dominant effect is lowering triglycerides, with a modest rise in HDL and little reliable effect on ASCVD outcomes.
Because of that, fibrates are not a substitute for statins in routine cardiovascular risk reduction. Their clear indication is severe hypertriglyceridemia — generally a triglyceride level of ≥ 500 mg/dL — where the immediate goal is to prevent acute pancreatitis rather than to lower LDL.
Key point for boards: When a question describes triglycerides in the high hundreds or thousands, the priority shifts from LDL to preventing pancreatitis — and a fibrate (or omega-3 fatty acids) becomes the answer.
If a fibrate must be combined with a statin, fenofibrate is preferred over gemfibrozil. Gemfibrozil inhibits the glucuronidation pathway that clears many statins, raising statin plasma concentrations and markedly increasing the risk of statin-associated myopathy. Other fibrate adverse effects to know: gallstones and a reversible rise in serum creatinine.
Niacin: Largely Obsolete for Add-On Therapy
Niacin (nicotinic acid) has the most favorable-looking effect on the lipid panel of the three classes — it raises HDL, lowers triglycerides, and lowers LDL. On paper, that seems ideal.
In practice, large outcome trials (AIM-HIGH, HPS2-THRIVE) showed that adding niacin to statin therapy did not reduce cardiovascular events and increased adverse effects. As a result, niacin is no longer recommended as routine add-on therapy and has largely been displaced by agents with actual outcome data.
Key point for boards: Niacin's lipid effects look impressive, but the outcome trials are the deciding factor. The AANP and ANCC test whether you know the evidence, not just the mechanism.
Niacin's adverse-effect profile is heavily tested:
- Flushing — the most common effect; pre-treatment with aspirin and taking the dose with food reduces it
- Hyperglycemia — can worsen glycemic control in diabetes
- Hyperuricemia — can precipitate gout
- Hepatotoxicity — particularly with sustained-release formulations
Comparing Statins, Fibrates, and Niacin
| Feature | Statins | Fibrates | Niacin |
|---|---|---|---|
| Primary lipid effect | Lowers LDL | Lowers triglycerides | Raises HDL; lowers TG and LDL |
| Mechanism | HMG-CoA reductase inhibition | PPAR-alpha agonism | Nicotinic acid receptor agonism; reduces hepatic VLDL secretion |
| ASCVD outcome benefit | Strong | Limited | Not shown as add-on |
| Main indication | First-line ASCVD risk reduction | Severe hypertriglyceridemia (TG ≥ 500 mg/dL) | Rarely used; statin-intolerant niche only |
| Key adverse effects | Myalgia, rare myopathy, mild LFT elevation | Myopathy (esp. with gemfibrozil), gallstones, ↑ creatinine | Flushing, hyperglycemia, hyperuricemia/gout, hepatotoxicity |
Where Modern Add-On Agents Fit
The original "statins, fibrates, or niacin" framing has expanded. When a statin alone is insufficient, current practice favors ezetimibe or a PCSK9 inhibitor for additional LDL lowering, and icosapent ethyl (a purified omega-3, validated in the REDUCE-IT trial) for residual cardiovascular risk in selected patients with elevated triglycerides. Bempedoic acid is an option for statin-intolerant patients. Knowing that these agents have displaced niacin as add-on therapy is increasingly testable on both the AANP and ANCC exams.
Putting It Together
For board questions, follow this logic: if the goal is cardiovascular risk reduction, choose a statin and select intensity by benefit group. If the triglycerides are severely elevated and the concern is pancreatitis, choose a fibrate (or omega-3). And recognize that niacin, despite its attractive lipid effects, is not a preferred add-on because it failed to improve outcomes.
Board-Style Practice Questions
1. A 58-year-old patient with a history of myocardial infarction needs lipid therapy. What statin intensity is indicated?
Show Answer
2. A patient's lab work shows a triglyceride level of 850 mg/dL. Which drug class is most appropriate, and what is the primary goal?
Show Answer
3. Why is niacin not recommended as routine add-on therapy to a statin?
Show Answer
4. If a fibrate must be combined with a statin, which fibrate is preferred and why?
Show Answer
FAQ
Are statins, fibrates, or niacin the first-line lipid-lowering therapy?
When should a fibrate be used instead of a statin?
Why is niacin no longer commonly recommended?
What is the difference between high-intensity and moderate-intensity statin therapy?
How is niacin-induced flushing managed?
Conclusion
Choosing between statins, fibrates, or niacin on the NP boards comes down to the clinical goal. Statins are first-line for cardiovascular risk reduction and are dosed by intensity and benefit group — high-intensity for clinical ASCVD and LDL ≥ 190 mg/dL, at least moderate for diabetes in the 40–75 window. Fibrates have a narrow role in severe hypertriglyceridemia to prevent pancreatitis. Niacin, despite favorable lipid effects, is largely obsolete because it did not improve outcomes when added to a statin.
Source:
Grundy, Scott M. “2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol.” Circulation, vol. 139, no. 25, 10 Nov. 2019, www.ahajournals.org/doi/10.1161/CIR.0000000000000625, https://doi.org/10.1161/cir.0000000000000625.
